Viridian Therapeutics Inc (VRDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.51B
Last updated: Nov 17, 2026 at 4:14 PM ET
Viridian Therapeutics Inc (VRDN) Stock Chart
Viridian Therapeutics (VRDN) has a latest price of $30.06 on Nov 17, 2026, 12.3% below its 52-week high of $34.29. Its price rose 4.5% over the past 12 months. The month-end price fell 69.5% over the 10 years through Oct 2026, a compound annual decline of 11.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $205.10 in Jul 2017 and its lowest $6.69 in Mar 2020, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart VRDN with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for VRDN.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 21.2%, and over 6 months it rose 88.2%. The month-end price rose 97.4% over the 3 years through Oct 2026, a compound annual rate of 25.4%.
| Period | Change |
|---|---|
| 1 month | +44.5% |
| 3 months | +21.2% |
| 6 months | +88.2% |
| 12 months | +4.5% |
| 12 months, with dividends | +4.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +97.4% | +25.4% |
| 5 years | +36.3% | +6.4% |
| 10 years | -69.5% | -11.2% |
Price by Year
Its best calendar year was 2020, when the price rose 128.6%, and its weakest was 2019, when it fell 84.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $24.67 | -20.7% |
| 2025 | $31.12 | +62.3% |
| 2024 | $19.17 | -12.0% |
| 2023 | $21.78 | -25.4% |
| 2022 | $29.21 | +47.7% |
| 2021 | $19.77 | +20.2% |
| 2020 | $16.45 | +128.6% |
| 2019 | $7.20 | -84.2% |
| 2018 | $45.43 | -70.9% |
| 2017 | $156.37 | +108.2% |
Trading Range
The price is 30.6% above its 50-day average of $23.02 and 39.7% above its 200-day average of $21.52.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $30.06 | |
| 52-week high | $34.29 | -12.3% |
| 52-week low | $13.18 | +128.1% |
| 50-day average | $23.02 | +30.6% |
| 200-day average | $21.52 | +39.7% |
Price Risk
Over 3 years, its largest fall from a peak was 60.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.11 |
| Largest fall, 1 year | -60.6% |
| Largest fall, 3 years | -60.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About VRDN
What is VRDN's 1-year price change?
Viridian Therapeutics's price rose 4.5% over the past 12 months. With dividends included, the 12-month total return was 4.5%.
What is VRDN's 5-year price change?
Viridian Therapeutics's month-end price rose 36.3% over the 5 years through Oct 2026, a compound annual rate of 6.4%. These figures leave out dividends.
What is VRDN's 52-week high and low?
Viridian Therapeutics's 52-week high is $34.29 and its 52-week low is $13.18. Its latest price of $30.06 on Nov 17, 2026 is 12.3% below the high.
What is VRDN's beta?
Viridian Therapeutics's 1-year beta against the S&P 500 is 1.11, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 60.6%.
Is the VRDN chart free?
Yes. Advanced Charting for VRDN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
VRDN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors